Finding new treatments for antibiotic-resistant bacterial infections
Overcoming Resistance to Novel Bacterial Topoisomerase Inhibitors
This study is looking at new medicines to help fight tough infections like MRSA that don't respond to regular antibiotics, so patients can have better treatment options when dealing with these resistant germs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10992154 on NIH RePORTER |
What this research studies
This research focuses on developing new antibacterial agents to combat the growing problem of antibiotic resistance, particularly against Methicillin-resistant Staphylococcus aureus (MRSA). The team is investigating a new class of drugs called Novel Bacterial Type II Topoisomerase Inhibitors (NBTIs), which work by targeting essential bacterial enzymes. By understanding how bacteria develop resistance to these new drugs, the researchers aim to create more effective treatments. Patients may benefit from these advancements through improved options for treating resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with infections caused by MRSA or other antibiotic-resistant bacteria.
Not a fit: Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new and effective treatment options for patients suffering from antibiotic-resistant infections.
How similar studies have performed: Previous research has shown promise in developing new antibacterial agents targeting similar mechanisms, indicating a potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Mitton-Fry, Mark J. — Ohio State University
- Study coordinator: Mitton-Fry, Mark J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.